Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2.

Autor:	Taşlı NP; Faculty of Engineering, Yeditepe University, Istanbul, Turkey., Gönen ZB; Oral and Maxillofacial Surgery, Genome and Stem Cell Centre, Erciyes University, Kayseri, Turkey., Kırbaş OK; Faculty of Engineering, Yeditepe University, Istanbul, Turkey., Gökdemir NS; Oral and Maxillofacial Surgery, Genome and Stem Cell Centre, Erciyes University, Kayseri, Turkey., Bozkurt BT; Faculty of Engineering, Yeditepe University, Istanbul, Turkey., Bayrakcı B; Faculty of Engineering, Yeditepe University, Istanbul, Turkey., Sağraç D; Faculty of Engineering, Yeditepe University, Istanbul, Turkey., Taşkan E; Faculty of Engineering, Yeditepe University, Istanbul, Turkey., Demir S; Faculty of Engineering, Yeditepe University, Istanbul, Turkey., Ekimci Gürcan N; Faculty of Medicine, Yeditepe University, Istanbul, Turkey., Bayındır Bilgiç M; Faculty of Medicine, Yeditepe University, Istanbul, Turkey., Bayrak ÖF; Faculty of Medicine, Yeditepe University, Istanbul, Turkey., Yetişkin H; Faculty of Medicine, Erciyes University, Kayseri, Turkey.; Vaccine Research and Development Application and Research Center, Erciyes University, Kayseri, Turkey., Kaplan B; Faculty of Medicine, Erciyes University, Kayseri, Turkey.; Vaccine Research and Development Application and Research Center, Erciyes University, Kayseri, Turkey., Pavel STI; Faculty of Medicine, Erciyes University, Kayseri, Turkey.; Vaccine Research and Development Application and Research Center, Erciyes University, Kayseri, Turkey., Dinç G; Faculty of Medicine, Erciyes University, Kayseri, Turkey., Serhatlı M; The Scientific and Technological Research Council of Turkey (TÜBITAK) Marmara Research Centre Energy Institute, Kocaeli, Turkey., Çakırca G; The Scientific and Technological Research Council of Turkey (TÜBITAK) Marmara Research Centre Energy Institute, Kocaeli, Turkey.; Department of Molecular Biology and Genetics, Faculty of Science, Gebze Technical University, Kocaeli, Turkey., Eken A; Department of Biology, Faculty of Science, Erciyes University, Kayseri, Turkey.; Gevher Nesibe Genome and Stem Cell Institute, Erciyes University, Kayseri, Turkey., Aslan V; Antalya Training and Research Hospital, Antalya, Turkey., Yay M; Faculty of Medicine, Erciyes University, Kayseri, Turkey., Karakukcu M; Faculty of Medicine, Erciyes University, Kayseri, Turkey., Unal E; Faculty of Medicine, Erciyes University, Kayseri, Turkey., Gül F; Department of Anesthesiology and Reanimation, School of Medicine, Marmara University, Istanbul, Turkey., Basaran KE; Faculty of Medicine, Erciyes University, Kayseri, Turkey.; Gevher Nesibe Genome and Stem Cell Institute, Erciyes University, Kayseri, Turkey., Ozkul Y; Faculty of Medicine, Erciyes University, Kayseri, Turkey.; Gevher Nesibe Genome and Stem Cell Institute, Erciyes University, Kayseri, Turkey., Şahin F; Faculty of Engineering, Yeditepe University, Istanbul, Turkey., Jones OY; Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, United States., Tekin Ş; The Scientific and Technological Research Council of Turkey (TÜBITAK) Marmara Research Centre Energy Institute, Kocaeli, Turkey.; Medical Biology, Department of Basic Medical Sciences, University of Health Sciences, Istanbul, Turkey., Özdarendeli A; Faculty of Medicine, Erciyes University, Kayseri, Turkey.; Vaccine Research and Development Application and Research Center, Erciyes University, Kayseri, Turkey., Cetin M; Faculty of Medicine, Erciyes University, Kayseri, Turkey.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Mar 24; Vol. 13, pp. 824378. Date of Electronic Publication: 2022 Mar 24 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.824378
Abstrakt:	The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Taşlı, Gönen, Kırbaş, Gökdemir, Bozkurt, Bayrakcı, Sağraç, Taşkan, Demir, Ekimci Gürcan, Bayındır Bilgiç, Bayrak, Yetişkin, Kaplan, Pavel, Dinç, Serhatlı, Çakırca, Eken, Aslan, Yay, Karakukcu, Unal, Gül, Basaran, Ozkul, Şahin, Jones, Tekin, Özdarendeli and Cetin.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu